Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis

被引:25
|
作者
Bsteh, Gabriel [1 ]
Hegen, Harald [2 ]
Altmann, Patrick [1 ]
Auer, Michael [2 ]
Berek, Klaus [2 ]
Di Pauli, Franziska [2 ]
Wurth, Sebastian [3 ]
Zinganell, Anne [2 ]
Rommer, Paulus [1 ]
Deisenhammer, Florian [2 ]
Leutmezer, Fritz [1 ]
Berger, Thomas [1 ]
机构
[1] Med Univ Vienna, Dept Neurol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[3] Med Univ Graz, Dept Neurol, Graz, Austria
关键词
progression independent of relapse activity; multiple sclerosis; optical coherence tomography; retinal thinning; biomarker; progression; DIGIT MODALITIES TEST; MS;
D O I
10.1177/2055217320966344
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background PIRA (progression independent of relapse) has emerged as a term to quantify the proportion of disability worsening due to non-inflammatory neurodegenerative processes in multiple sclerosis (MS). Objective To determine the impact of PIRA on retinal thinning, a biomarker of neuroaxonal degeneration in MS, in comparison to traditional disability worsening and relapse. Methods In a 4-year, prospective observational study including 171 relapsing MS (RMS) patients, retinal thinning was determined by annual spectral-domain optical coherence tomography measuring macular ganglion-cell-and-inner-plexiform-layer (GCIPL) and peripapillary-retinal-nerve-fibre-layer (pRNFL). PIRA was defined as an expanded disability status scale (EDSS) or symbol digit modalities test (SDMT) worsening confirmed after 24weeks with no relapse in the 30days before or after the disability worsening. Results Each PIRA event was associated with a mean additional loss of GCIPL (1.8 mu m) and pRNFL (1.9 mu m), similar to the impact of EDSS and SDMT worsening. Overall relapse and relapse without subsequent EDSS worsening did not influence retinal thinning, while a relapse with EDSS worsening was associated with an additional loss of GCIPL (1.3 mu m) and pRNFL (1.4 mu m). Conclusions PIRA is associated with retinal thinning, likely reflecting neurodegenerative processes, not directly associated with focal inflammation. It might be a clinical measure to identify MS patients with ongoing MS-associated neurodegeneration.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Progression Independent of Relapse Activity in Multiple Sclerosis More, or Less, Than Meets the Eye?
    Cruciani, Alessandro
    Toosy, Ahmed T.
    NEUROLOGY, 2025, 104 (02)
  • [42] Cerebrospinal fluid cellular transcriptome profiling of multiple sclerosis progression independent of relapse activity
    Marastoni, Damiano
    Turano, Ermanna
    Patane, Francesco
    Cavagna, Arianna
    Virla, Federica
    Anni, Daniela
    Tamanti, Agnese
    Camera, Valentina
    Eccher, Chiara
    Zanetti, Giulia
    Griggio, Francesca
    Castellucci, Monica
    Zenaro, Elena
    Bonetti, Bruno
    Romualdi, Chiara
    Calabrese, Massimiliano
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 500 - 501
  • [43] Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis
    Ciccarelli, Olga
    Barkhof, Frederik
    Calabrese, Massimiliano
    De Stefano, Nicola
    Eshaghi, Arman
    Filippi, Massimo
    Gasperini, Claudio
    Granziera, Cristina
    Kappos, Ludwig
    Rocca, Maria A.
    Rovira, Alex
    Sastre-Garriga, Jaume
    Sormani, Maria Pia
    Tur, Carmen
    Toosy, Ahmed T.
    NEUROLOGY, 2024, 103 (01)
  • [44] Progression independent of relapse activity and relapse-associated worsening predict future disability on multiple clinical domains
    Tur, Carmen
    Carbonell, Pere
    Cobo Calvo, Alvaro
    Otero-Romero, Susana
    Guio-Sanchez, Claudia
    Arrambide, Georgina
    Midaglia, Luciana
    Castillo-Justribo, Joaquin
    Vidal-Jordana, Angela
    Rodriguez, Breogan
    Beltran, Jordina
    Mongay-Ochoa, Neus
    Vilaseca, Andreu
    Arino, Helena
    Zabalza, Ana
    Bollo, Luca
    Pappolla, Agustin
    Jesus Arevalo, Maria
    Galan, Ingrid
    Nos, Carlos
    Comabella, Manuel
    Rio, Jordi
    Pareto, Deborah
    Sastre-Garriga, Jaume
    Rovira Canellas, Alex
    Tintore, Mar
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 422 - 423
  • [45] A novel retinal phenotype in multiple sclerosis is predictive of inflammatory disease activity and disability progression
    Saidha, S.
    Sotirchos, E.
    Ibrahim, M.
    Gelfand, J.
    Sepah, Y.
    Ratchford, J.
    Oh, J.
    Seigo, M.
    Newsome, S.
    Balcer, L.
    Frohman, E.
    Crainiceanu, C.
    Green, A.
    Nguyen, Q.
    Calabresi, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 10 - 11
  • [46] Relapse associated worsening and progression independent of relapse according to age in multiple sclerosis
    Iaffaldano, P.
    Lucisano, G.
    Manni, A.
    Simone, M.
    Paolicelli, D.
    Romeo, M.
    Morra, V. Brescia
    Patti, F.
    Zaffaroni, M.
    Gasperini, C.
    De Luca, G.
    Ferraro, D.
    Granella, F.
    Pozzilli, C.
    Romano, S.
    Gallo, P.
    Bergamaschi, R.
    Coniglio, M. G.
    Lus, G.
    Vianello, M.
    Banfi, P.
    Amato, M. P.
    Filippi, M.
    Trojano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 452 - 453
  • [47] Relapse-independent multiple sclerosis progression under natalizumab
    Graf, Jonas
    Leussink, Verena, I
    Soncin, Giulia
    Lepka, Klaudia
    Meinl, Ingrid
    Kumpfel, Tania
    Meuth, Sven G.
    Hartung, Hans-Peter
    Havla, Joachim
    Aktas, Orhan
    Albrecht, Philipp
    BRAIN COMMUNICATIONS, 2021, 3 (04)
  • [48] The comparative effectiveness of natalizumab and ocrelizumab in naive relapsing remitting multiple sclerosis: the impact on relapse dependent and relapse independent disability progression
    Iaffaldano, Pietro
    Lucisano, Giuseppe
    Guerra, Tommaso
    Paolicelli, Damiano
    Inglese, Matilde
    Foschi, Matteo
    Patti, Francesco
    Granella, Franco
    Romano, Silvia
    Cavalla, Paola
    De Luca, Giovanna
    Gallo, Paolo
    Bellantonio, Paolo
    Gallo, Antonio
    Montepietra, Sara
    Di Sapio, Alessia
    Vianello, Marika
    Quatrale, Rocco
    Spitaleri, Daniele
    Clerici, Raffaella
    Clerici, Valentina Torri
    Cocco, Eleonora
    Morra, Vincenzo Brescia
    Marfia, Girolama Alessandra
    Filippi, Massimo
    Amato, Maria Pia
    Trojano, Maria
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 368 - 369
  • [49] Metabolomics associated with relapse rate and disability progression in relapse remitting multiple sclerosis patients
    Kitsos, D.
    Sideri, E.
    Chondrogianni, M.
    Tsivgoulis, A.
    Zompola, C.
    Thomaidis, N.
    Voumvourakis, K.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 938 - 938
  • [50] Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis
    Bsteh, Gabriel
    Berek, Klaus
    Hegen, Harald
    Altmann, Patrick
    Wurth, Sebastian
    Auer, Michael
    Zinganell, Anne
    Di Pauli, Franziska
    Rommer, Paulus
    Leutmezer, Fritz
    Deisenhammer, Florian
    Berger, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) : 684 - 694